Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
Reinforcing commitment to ethical and sustainable growth
AINU is set to accelerate its expansion footprint, enhance operational capabilities
The agreement complements other PPAs for Sandoz production sites globally
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Subscribe To Our Newsletter & Stay Updated
